THE FUTURE OF PERSONALIZED MEDICINE IN LOW- INCOMECOUNTRIES

• NAVEED SHUJA

  Author

In recent decades, the landscape of global healthcare has been rapidly transformed by the emergence of personalized medicine an approach that tailor’s diagnosis, prevention, and treatment to the individual’s genetic, environmental, and lifestyle factors¹. In high-income nations, this model is already reshaping clinical practice, especially in fields like oncology, cardiology, and rare genetic disorders. Yet for low-income countries (LICs), where health systems are often constrained by limited resources, infrastructure gaps, and competing health priorities, the promise of personalized medicine remains distant. The critical question today is not whether personalized medicine can reach these regions, but how it can be made accessible, equitable, and sustainable².

 Understanding the Promise:

Personalized medicine moves beyond the traditional “one-size-fits-all” model of healthcare. It allows clinicians to predict disease susceptibility, diagnose conditions earlier, and select treatments that are more effective and less toxic. For example, genetic profiling can help identify which cancer therapy is most likely to succeed for a specific patient, while pharmacogenomics can determine drug dosing tailored to an individual’s metabolism³. In infectious diseases, understanding host–pathogen interactions can inform precision vaccination strategies. These advances have profound implications for LICs, where the burden of both communicable and non-communicable diseases is rising. The potential to optimize resource use, avoid ineffective treatments, and reduce hospital stays could have a direct economic impact on already strained health systems⁴.

 The Challenge of Inequity:

However, despite its potential, personalized medicine risks deepening existing global health inequalities. Most advances in genomic research, biobanking, and precision therapeutics are concentrated in high-income countries⁵. Populations in LICs are underrepresented in genomic databases, meaning therapies designed on the basis of these data may be less effective or even irrelevant for them. Moreover, implementing personalized medicine requires infrastructure and human capital that are often lacking. Next-generation sequencing machines, advanced diagnostic laboratories, bioinformatics capabilities, and reliable electronic health records are rare in resource-limited settings. There is also a shortage of trained specialists—geneticists, molecular biologists, clinical pharmacologists—who are essential to translate genomic findings into clinical practice⁶.

 Cost: A Major Barrier;

Cost remains one of the most formidable barriers. Genomic testing, targeted therapies, and biologics are expensive, and health insurance coverage in many LICs is either minimal or absent. For health systems already struggling to provide basic care like maternal health services or vaccination, personalized medicine may appear to be a distant luxury⁷. Yet, costs are not static. Sequencing costs have dropped dramatically over the past decade, and several global initiatives are driving further reductions. If these trends continue, affordable precision tools could become a reality even in resource-limited environments. The challenge is ensuring that cost reductions are matched by strategic investment in local capacity building⁸.

 Building the Foundation: Local Capacity and Data;

A sustainable personalized medicine strategy for LICs must begin with local data generation. Genomic diversity in many African and Asian populations is immense but poorly documented. Establishing regional biobanks and genomic databases is essential to create treatment approaches relevant to local populations^3-6. This requires governments, research institutions, and international organizations to work together. Equally important is capacity building. Training local scientists, clinicians, and laboratory technicians can ensure that personalized medicine does not become another imported solution but grows from within health systems. Universities and teaching hospitals must integrate molecular diagnostics and genomic medicine into their curricula to prepare the next generation of healthcare providers⁹.

 Leveraging Technology and Innovation:

Telemedicine, mobile health applications, and cloud-based data platforms can help bridge infrastructure gaps in LICs. For example, local clinics may collect patient samples and send genomic data to centralized laboratories for analysis, with results delivered electronically. Such hybrid models can lower costs while expanding access¹⁰. Artificial intelligence (AI) also holds promise in simplifying complex data interpretation. In settings where genetic counselors are scarce, AI-driven decision support tools could help clinicians recommend tailored treatments. Moreover, open-source software and global research collaborations can reduce the dependency on expensive proprietary platforms¹¹.

Partnerships: A Shared Responsibility:

The advancement of personalized medicine in LICs cannot rest solely on national governments. It requires strong partnerships with international organizations, donor agencies, pharmaceutical companies, and academic institutions¹². Initiatives like the Human Heredity and Health in Africa (H3Africa) project have already shown how collaborative frameworks can enhance genomic research capacity in low-resource regions. Pharmaceutical companies also play a crucial role. By adopting tiered pricing strategies and voluntary licensing, they can make targeted therapies more affordable. Public–private partnerships can help build laboratory networks, train healthcare workers, and ensure equitable access to precision treatments¹⁰.

 Ethical and Regulatory Considerations:

Personalized medicine raises important ethical and regulatory challenges. Genomic data are highly sensitive, and in LICs where data protection laws may be weak or outdated, privacy and misuse risks are real. Establishing clear regulatory frameworks is essential to protect patient rights, ensure informed consent, and maintain public trust. Community engagement is also vital¹. For personalized medicine to succeed, people must understand the benefits, limitations, and safeguards surrounding the use of their genetic information. This requires culturally appropriate communication strategies and involvement of community leaders in public health planning^3,6.

 A Stepwise Approach:

Implementing personalized medicine in LICs should not be seen as an all-or-nothing endeavor. A stepwise approach starting with diseases that have the highest burden and the clearest precision medicine benefits can make the process more feasible^8,9. For example, applying pharmacogenomic testing to improve tuberculosis drug responses or using genetic screening for sickle cell disease could yield early, impactful successes. Pilot projects can help identify context-specific barriers, test cost-effectiveness, and build public trust. Gradually, this can expand to more complex disease areas such as cancer genomics and rare diseases¹⁰.

 A Call to Action:

The future of personalized medicine must be inclusive. Excluding low-income countries from this revolution would not only be unjust but also scientifically shortsighted, given the rich genetic diversity that could benefit global medical knowledge. By investing strategically in capacity building, collaboration, and ethical frameworks, LICs can move from being passive recipients of global health innovation to active contributors⁵. The goal is not to replicate high-income country models but to adapt and innovate locally. Personalized medicine in LICs may look different leaner, more decentralized, more reliant on digital tools but it can be equally effective and transformative. As the global medical community stands on the brink of a precision medicine era, equity must be at the center of the agenda. Governments, researchers, clinicians, and industry must work together to ensure that the benefits of this new frontier reach all people not just those who can afford it^10-12.

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795. doi:10.1056/NEJMp1500523.

2. Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119-2120.

3. Abubakar A, Malik M, Manzoor I, Alotaibi MS, Mirdamadi S. Challenges and opportunities for implementing personalized medicine in low and middle-income countries. Front Genet. 2021;12:619872. doi:10.3389/fgene.2021.619872

4. Rotimi C, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med. 2010;363(16):1551-1558.

5. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26-31. doi:10.1016/j.cell.2019.02.048

6. McMahon FJ. Pharmacogenetics in low- and middle-income countries: opportunities and challenges. Pharmacogenomics J. 2019;19(6):479-487. doi:10.1038/s41397-019-0074-5

7. Tekola-Ayele F, Rotimi CN. Translational genomics in low- and middle-income countries: Opportunities for precision public health. Genome Med. 2015;7:1-8. doi:10.1186/s13073-015-0195-6

8. Adoga MP, Fatumo SA, Agwale SM. H3Africa: a tipping point for a revolution in bioinformatics, genomics and health research in Africa. Source Code Biol Med. 2014;9:10. doi:10.1186/1751-0473-9-10.

9. Krittanawong C, Johnson KW, Roselli C, Khademi A, Wang Z, Ying X, et al. Artificial intelligence and precision medicine: Opportunities and challenges. Eur Heart J. 2019;40(22):1798-1806. doi:10.1093/eurheartj/ehy564

10. Moodley K, Kleinsmidt A. Ethical issues in genomic research in low-income settings. BMC Med Ethics. 2021;22(1):1-9. doi:10.1186/s12910-021-00650-8

11. World Health Organization. Ethics and governance of artificial intelligence for health. Geneva: WHO; 2021.

12. Dzau VJ, Ginsburg GS. Realizing the full potential of precision medicine in global health. Sci Transl Med. 2016;8(336):336ps11. doi:10.1126/scitranslmed.aaf6852

• PDF

Copyright (c) 2025 NAVEED SHUJA (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.